You are here

Early Response to Certolizumab Pegol Predicts Long-Term Efficacy in Rheumatoid Arthritis

Rheumatologist Michael Weinblatt, MD, of Brigham and Women’s Hospital, discusses a post hoc analysis showing that rheumatoid arthritis patients’ response to certolizumab pegol and methotrexate after 12 weeks of treatment strongly predicts whether they’ll achieve sustained remission in the future with this regimen or should try other therapies.

American College of Rheumatology, November 2015